Shared on11 Aug 25Fair value Increased 14%
CytomX Therapeutics’ consensus price target has increased notably, driven by a substantially higher expected P/E despite a decline in net profit margin, resulting in a revised fair value of $5.75 per share. What's in the News First patient dosed with CX-801 in combination with KEYTRUDA in a Phase 1 dose escalation study for metastatic melanoma.
Shared on01 May 25
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on23 Apr 25
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on17 Apr 25Fair value Decreased 3.82%
AnalystConsensusTarget has decreased profit margin from 19.3% to 17.3% and increased future PE multiple from 62.5x to 72.3x.
Shared on09 Apr 25
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on02 Apr 25Fair value Increased 6.07%
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on26 Mar 25
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on19 Mar 25
AnalystConsensusTarget has increased profit margin from 15.8% to 19.6% and decreased future PE multiple from 75.6x to 61.0x.
Shared on11 Mar 25Fair value Decreased 11%
AnalystConsensusTarget made no meaningful changes to valuation assumptions.